Biogen (NASDAQ:BIIB) Releases FY 2026 Earnings Guidance

Biogen (NASDAQ:BIIB) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 15.250-16.250 for the period, compared to the consensus estimate of 14.940. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Jefferies Financial Group increased their price target on Biogen from $190.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, November 28th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $225.00 price objective on shares of Biogen in a report on Thursday, January 8th. Wall Street Zen lowered shares of Biogen from a “buy” rating to a “hold” rating in a report on Sunday, November 9th. Guggenheim upped their price target on shares of Biogen from $165.00 to $185.00 in a research note on Friday, October 31st. Finally, Sanford C. Bernstein set a $191.00 target price on shares of Biogen in a report on Tuesday. Eleven equities research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. According to data from MarketBeat.com, Biogen has an average rating of “Hold” and a consensus target price of $194.23.

Biogen Trading Up 8.5%

Shares of BIIB opened at $201.18 on Friday. The company’s fifty day simple moving average is $176.94 and its 200-day simple moving average is $156.87. The company has a market cap of $29.51 billion, a P/E ratio of 22.84, a P/E/G ratio of 1.70 and a beta of 0.16. The company has a current ratio of 2.72, a quick ratio of 2.04 and a debt-to-equity ratio of 0.35. Biogen has a twelve month low of $110.04 and a twelve month high of $202.41.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The company had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the prior year, the firm posted $3.44 EPS. The firm’s revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, analysts expect that Biogen will post 15.83 EPS for the current year.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 748 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total value of $134,116.40. Following the sale, the insider directly owned 6,271 shares in the company, valued at approximately $1,124,390.30. This represents a 10.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.18% of the company’s stock.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat on both EPS ($1.99 vs. consensus ~1.72) and revenue ($2.28B vs. ~$2.21B); investors reacted favorably to the upside. BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat ’26 EPS View
• Positive Sentiment: Biogen raised FY‑2026 adjusted EPS guidance to $15.25–$16.25, above consensus — a major driver of the rally as it signals stronger full‑year profitability expectations. Biogen forecasts annual profit above estimates as Leqembi sales pick up
• Positive Sentiment: Sales of Leqembi and newer launches (Skyclarys, Zurzuvae) showed meaningful growth and helped offset MS declines, supporting upside to future revenue mix and margins. Biogen Hits 52-Week High, Alzheimer’s Drug Sales Jump
• Positive Sentiment: Recent analyst support (RBC buy) and favorable coverage helped sentiment alongside the earnings/guidance beat. Biogen (BIIB) Receives a Buy from RBC Capital
• Neutral Sentiment: Management released the full earnings slide deck and call transcript — useful for modeling guidance assumptions and product-level trends but not market-moving on its own. Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Core MS franchise continued to decline, driving overall revenue down ~7.2% YoY; management said MS revenue pressures will persist, which limits near‑term top‑line growth. Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide
• Negative Sentiment: Some outlets note Biogen “swung to a loss” on certain GAAP measures and expect continued portfolio declines, underlining execution and pricing risks in legacy products. Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles

Institutional Trading of Biogen

Several institutional investors and hedge funds have recently made changes to their positions in the business. CIBC Private Wealth Group LLC increased its stake in Biogen by 8.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock worth $167,000 after buying an additional 89 shares during the period. CIBC Bancorp USA Inc. bought a new position in Biogen in the 3rd quarter worth about $3,585,000. Captrust Financial Advisors grew its stake in Biogen by 13.3% in the 3rd quarter. Captrust Financial Advisors now owns 16,532 shares of the biotechnology company’s stock worth $2,316,000 after acquiring an additional 1,937 shares in the last quarter. Coldstream Capital Management Inc. increased its position in shares of Biogen by 38.0% during the third quarter. Coldstream Capital Management Inc. now owns 4,480 shares of the biotechnology company’s stock worth $628,000 after acquiring an additional 1,234 shares during the period. Finally, Danske Bank A S bought a new stake in shares of Biogen during the third quarter valued at approximately $6,263,000. 87.93% of the stock is currently owned by institutional investors.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.